Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Ahn, MJ; Cho, BC; Felip, E; Korantzis, I; Ohashi, K; Majem, M; Juan-Vidal, O; Handzhiev, S; Izumi, H; Lee, JS; Dziadziuszko, R; Wolf, J; Blackhall, F; Reck, M; Alvarez, JB; Hummel, HD; Dingemans, AMC; Sands, J; Akamatsu, H; Owonikoko, TK; Ramalingam, SS; Borghaei, H; Johnson, ML; Huang, S; Mukherjee, S; Minocha, M; Jiang, TY; Martinez, P; Anderson, ES; Paz-Ares, L

Paz-Ares, L (通讯作者)，Univ Complutense Madrid, Hosp Univ 12 Octubre, CNIO H12o Lung Canc Unit, Ave Andalucia S-N, Madrid 28041, Spain.;Paz-Ares, L (通讯作者)，Ciberonc, Ave Andalucia S-N, Madrid 28041, Spain.

NEW ENGLAND JOURNAL OF MEDICINE, 2023; 389 (22): 2063

Abstract

BackgroundTarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索